...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Clevudine for hepatitis B.
【24h】

Clevudine for hepatitis B.

机译：克留夫定治疗乙型肝炎。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Clevudine is distinguished from other oral agents by its sustained suppression of HBV DNA for several months after cessation of therapy, according to a comprehensive review of hepatitis B in the 2 October 2008 issue of the New England Journal of Medicine. Clevudine is differentiated by i) an unusual activation pathway to the biochemically active triphosphate; ii) a mechanism of action of clevudine triphosphate that inhibits multiple steps of the hepatitis B virus (HBV) intracellular life cycle; iii) a long half-life and iv) significant reduction of covalently closed circular DNA (cccDNA) in animal models. Clevudine was approved and is marketed in South Korea based on two 24-week phase III trials vs. placebo. In these studies with treatment-na?ve patients, 59% of 248 HBeAg-positive patients had undetectable HBV DNA after 24 weeks of treatment compared with 92% of 89 HBeAg-negative patients, while the percentage of patients with normal liver enzymes was 68% in the HBeAg-positive patients and 75% in the HBeAg-negative patients (all statistically significant versus placebo). Follow-up studies include trials vs. lamivudine as well as a phase IV study of long-term clevudine. Larger and longer phase III trials in the United States, European Union, Asia and South America of clevudine vs. adefovir are ongoing. An ANRS-sponsored trial of clevudine vs. tenofovir vs. the combination of the two agents is poised to begin. Literature published through November 2008 and presentations from the 59th annual meeting of the American Association for the Study of Liver Diseases held 31 October to 4 November 2008 are included.
机译：2008年10月2日在《新英格兰医学杂志》上对乙型肝炎进行的全面审查显示，克列夫定与其他口服药物的区别在于，它在停止治疗后可持续抑制HBV DNA数月。克列夫定的区别在于：i）异常的生化活性三磷酸活化途径; ii）三磷酸克列夫定的作用机制可抑制乙型肝炎病毒（HBV）细胞内生命周期的多个步骤; iii）长的半衰期，iv）动物模型中的共价闭合环状DNA（cccDNA）显着降低。基于两项与安慰剂相比的24周III期临床试验，Clevudine已获批准并在韩国上市。在这些未经治疗的患者的研究中，治疗24周后248名HBeAg阳性患者中有59％的患者无法检测到HBV DNA，而89名HBeAg阴性患者中的92％的患者中肝酶水平为68％在HBeAg阳性患者中占％，在HBeAg阴性患者中占75％（与安慰剂相比，所有数据均具有统计学意义）。后续研究包括拉米夫定与拉米夫定的临床试验，以及长期服用克列夫定的IV期研究。目前正在美国，欧洲联盟，亚洲和南美进行克雷夫定与阿德福韦的更大，更长的III期临床试验。由ANRS赞助的克罗夫定与替诺福韦与两种药物联合治疗的试验即将开始。包括截至2008年11月的文献和2008年10月31日至11月4日举行的美国肝病研究协会第59届年会的演讲。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号